4th Annual MarketsandMarkets Epigenetics Congress

3 - 4 October 2019 | London-UK
CONFERENCE SPEAKERS
Advisors
Prof. Frank Dekker
Prof. Frank Dekker
Professor, Medicinal Chemistry, Chemical Biology ,
University of Groningen, Netherlands


Frank J. Dekker was born in The Netherlands, in 1977. He received his Ph.D. in Medicinal Chemistry from Utrecht University, the Netherlands in 2004. Subsequently, he moved to the Max-Planck Institute for molecular physiology in Dortmund, Germany for postdoctoral research. In 2007, he moved to the University of Groningen, The Netherlands as an assistant professor. Since 2012 he has been promoted to associate professor at the same university and is now part of the department Chemical and Pharmaceutical Biology. His research has been funded by a VIDI grant for the Netherlands Organisation of scientific research and by an ERC starting investigator grant from the European Union, which are both prestigious personal grants  His current research interests are Medicinal Chemistry, Enzyme inhibition, Pharmacology, Epigenetics, Lipid signaling, and Inflammation.


Rene Bartz
Rene Bartz
Manager, Development Products,
4SC, Germany



Speakers
Dr. Tamara Maes
Dr. Tamara Maes
Chief Scientific Officer,
Oryzon, Spain



Dan Dransfield
Dan Dransfield
Vice President, Biology ,
Epizyme



Rachel Grimley
Rachel Grimley
Executive Director, Global Head, Mechanistic Biolo,
AstraZeneca



Panagis Filippakopoulos
Panagis Filippakopoulos
Associate Professor, Structural Genomics Consortiu,
University of Oxford



Ronan Murphy
Ronan Murphy
Assciate Editor, Clinical Epigenetics ,
Dublin City University


Currently Lecturer in Cell and Molecular Physiology, School of Health & Human Performance, DCU. Dr. Murphy started his research career as a Clinical Research Scientist and Core Facilities Director (Molecular Genetics) in the Centre for Cardiovascular Science, Royal College of Surgeons in Ireland (1996-2000). His group also studies epigenetics with respect to chronic disease management. He is currently Vice Chair for Europe’s largest COST Action- EpiChemBio (CM1406- http://epichembio.eu/) for Epigenetic Technologies and Applications and is an Editorial Board Member for Clinical Epigenetics. Current projects in this field include working with the European space agency (ESA) on the effect of space flight on cardiovascular epigenetics. Dr. Murphy’s group is collaborating with one of Ireland’s top 3 innovative companies -https://www.brainwavebank.com, to develop novel Disruptive Technologies to manage cognitive decline, dementia and inflammageing of the Neurovascular Compartment. He is currently Associate editor for Clinical Epigenetics and Frontiers in Physiology, and an Editorial board member for Journal of Cardiovascular Pharmacology.


Manfred Jung
Manfred Jung
Professor, Pharmaceutical Chemistry ,
University of Freiburg


Manfred Jung did his PhD at the University of Marburg in 1993, then worked as a postdoc with T. Durst at the University of Ottawa. From 1994 to 2003 he was a group leader at the University of Münster and obtained his habitation in Pharmaceutical Chemistry in 2000. Since 2003 he was a Professor of Pharmaceutical Chemistry at the University of Freiburg and since 2011 he is Full Professor there. In 2011/12 and for 2016/17 he was appointed as Senior Fellow at the Freiburg Institute of Advanced Studies (FRIAS). Prof. Jung was Dean of the Faculty of Chemistry and Pharmacy from 2015-2018 and is now Vice-Dean. The topic of his research is Chemical Epigenetics with a major focus on histone modifying enzymes. His group is working on inhibitor synthesis, assay development and screening for inhibitors of reversible histone acetylation and methylation, as well as methyl-lysine reader proteins.


Gavin Reynolds
Gavin Reynolds
Professor Emeritus ,
Queens University Belfast


Gavin Reynolds is Honorary Professor at Sheffield Hallam University and Professor Emeritus, previously Chair of Neuroscience, at Queen’s University Belfast. After a biochemistry PhD, he undertook postdoctoral work in London, Vienna and Cambridge, following which he held university posts in Nottingham, Sheffield and Belfast. His main research interests lie in two directions: the neurotransmitter pathology of schizophrenia, and the mechanisms underlying the beneficial and adverse effects of antipsychotics and other psychoactive drugs, with a recent focus on pharmacogenetic and epigenetic influences. He has over 300 research publications, including papers in Nature and The Lancet. He has international collaborations with Visiting Professor appointments in Thailand and China. He is Past-President of the British Association for Psychopharmacology.


Marcus Buschbeck
Marcus Buschbeck
Group Leader ,
Josep Carreras Leukaemia Institute



Nathaniel I. Martin
Nathaniel I. Martin
Professor, Biological Chemistry ,
University of Sylvius



Mikhail Spivakov
Mikhail Spivakov
Group leader and Honorary Senior Lecturer, MRC Lon,
Imperial College



Prof. Frank Dekker
Prof. Frank Dekker
Professor, Medicinal Chemistry, Chemical Biology ,
University of Groningen, Netherlands


Frank J. Dekker was born in The Netherlands, in 1977. He received his Ph.D. in Medicinal Chemistry from Utrecht University, the Netherlands in 2004. Subsequently, he moved to the Max-Planck Institute for molecular physiology in Dortmund, Germany for postdoctoral research. In 2007, he moved to the University of Groningen, The Netherlands as an assistant professor. Since 2012 he has been promoted to associate professor at the same university and is now part of the department Chemical and Pharmaceutical Biology. His research has been funded by a VIDI grant for the Netherlands Organisation of scientific research and by an ERC starting investigator grant from the European Union, which are both prestigious personal grants  His current research interests are Medicinal Chemistry, Enzyme inhibition, Pharmacology, Epigenetics, Lipid signaling, and Inflammation.


Inma Rioja
Inma Rioja
Senior Director & Portfolio Research Lead at Epige,
GSK


Inma Rioja is a Senior Biology Director at the Epigenetics Research Unit (GSK, UK) and the Portfolio Research Lead of Immuno-Epigenetics. She has more than 12 years of experience in R&D leading projects and teams, acting as Biology Leader, Project Leader (PL) and Early Development Leader (EDL) for bromodomain targets in the Epigenetics unit. Moreover, her expertise in immunology, epigenetics and drug discovery was consolidated during her three years of research in the Epi-Enzyme research unit (Epinova, iiTAU, GSK) with responsibilities for target validation and phenotypic compound characterisation together with coordinating academic collaborations and biology outsourcing activities. Prior to joining Epinova, she worked as a Principal Scientist in the Biomarker group within the Respiratory and Inflammation CEDD (GSK) focussing her research on the identification and validation of pharmacodynamic (PD) biomarkers and rheumatoid arthritis disease activity biomarkers at pre-clinical and clinical levels, supporting drug discovery. Inma joined GSK in 2006 after completing two post-docs, at GSK (UK) and INSERM (France), and a PhD in Pharmacology of Inflammation at the University of Valencia (Spain).


Christopher Schofield
Christopher Schofield
Head of Organic Chemistry,
University of Oxford and fellow of Royal society,


Chris Schofield studied for a degree in chemistry at the University of Manchester (1979-1982). In 1982 he moved to Oxford for DPhil studies with Jack Baldwin on the synthesis and biosynthesis of antibiotics. In 1985 he became a Departmental Demonstrator in the Dyson Perrins Laboratory, and in 1990 Lecturer in Chemistry and Fellow of Hertford College. In 1998 he became Professor of Chemistry, and in 2011 was appointed Head of Organic Chemistry. He is a Fellow of the Royal Society. His research group works at the interface of chemistry, biology and medicine. His work has opened up new fields in antibiotic research, oxygen sensing and gene regulation in organisms ranging from bacteria to plants and animals. His work has identified new opportunities for medicinal intervention that are being pursued by numerous academic and commercial laboratories.


Wouter De Jounge
Wouter De Jounge
Professor ,
NARCIS, Netherlands



Magnus Ivarsson
Magnus Ivarsson
VP, Head of Discovery ,
Rodin Therapeutics, USA



Shailendra Singh (Shelly)
Shailendra Singh (Shelly)
Chief Operating Officer,
MarketsandMarkets


Shailendra Singh (Shelly) is Chief Operating Officer of MnM and a member of its board. He focuses on global sales and client services functions, as well as commercial optimization at MarketsandMarkets. He has years of expe¬rience in global delivery and outsourcing sector in the IT/ Consulting/Analytics/Big Data sectors. Prior to MnM, he was leading the global sales, client services and commercial ef¬fectiveness functions for Mu Sigma, a unicorn company and a leading global provider of Decision Sciences and Big Data analytics solutions.


Alfredo Budillon
Alfredo Budillon
Chief Experimental Pharmacology Unit Department of,
Istituto Nazionale Tumori, Italy


Dr. Budillon graduated in Medicine and passed the Specialty Certification in Oncology at University Federico II, Naples, Italy. He obtained the PhD in Oncology from University G. D’Annunzio of Chieti, Italy, and a master’s degree in health economy, Management and Bioethics. He gained experience in biochemistry and antitumor experimental therapeutics as post-doc during a stage fellow at the National Cancer Institute, Bethesda, USA. Dr. Budillon is currently the chief of Experimental Pharmacology, National Cancer Institute G. Pascale, Naples, Italy. He is author of more than 130 publications. His research interest focusses on the molecular mechanism of novel anticancer drugs and the potential combination approaches between conventional and targeted based drugs, particularly epigenetic drugs. Other scientific interests are related with the identification of new predictive biomarkers for anticancer drugs as well as in proteomic/metabolomics approach in defining new molecular diagnostic and therapeutic targets.


Rémi Terranova
Rémi Terranova
Principle Investigator, Preclinical safety,
Novartis Institutes for BioMedical Research, Switz


Remi leads the Safety Epigenetics group within Novartis Institutes for Biomedical Research (NIBR) Preclinical Safety department since 2009. Through continuous development of tissue-based epigenomic profiling technologies, his group has been supporting the identification of novel pharmacodynamic epigenetic biomarkers of drug-induced toxicity, specifically supporting safety assessment of therapeutic epigenetic effectors through integration of tissue-based pharmacodynamic, pharmacokinetic and morphologic endpoints. His group, in collaboration with academic partners, also has a long-standing interest in investigating novel mechanistic insights & biomarkers for long-lasting drug-induced cellular perturbations such as non-genotoxic carcinogenesis and transgenerational effects. Prior to joining Novartis Remi supported throughout his Ph.D. and postdoctoral training in France, the UK and Switzerland various projects in a diverse area of epigenetics research (development, reprogramming, cancer, genomic imprinting).


Rene Bartz
Rene Bartz
Manager, Development Products,
4SC, Germany